Immunochemistry Diagnostic Devices and Equipment Market Report 2026

The immunochemistry diagnostic devices and equipment market size has grown rapidly in recent years. It will grow from $3.67 billion in 2025 to $4.11 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to expansion of clinical diagnostic testing volumes, rising prevalence of chronic and infectious diseases, growth in centralized diagnostic laboratories, increasing use of immunoassays in oncology and endocrinology, improvements in laboratory infrastructure.

The immunochemistry diagnostic devices and equipment market size is expected to see rapid growth in the next few years. It will grow to $6.22 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, rising adoption of automated laboratory systems, expansion of personalized medicine applications, growing investment in advanced diagnostic technologies, increasing focus on early disease detection. Major trends in the forecast period include increasing adoption of automated immunoassay analyzers, rising demand for high-sensitivity diagnostic reagents, growing use of multiplex testing platforms, expansion of laboratory automation solutions, enhanced focus on workflow efficiency and accuracy.

The increasing demand for personalized medicine is expected to drive the growth of the immunochemistry diagnostic devices and equipment market. Personalized medicine is an approach that tailors healthcare decisions and treatment strategies based on an individual’s unique genetic, genomic, and clinical characteristics, with the goal of optimizing patient outcomes and minimizing adverse effects. The rise in demand for personalized medicine is driven by growing awareness and acceptance of treatments that consider individual genetic, lifestyle, and environmental factors to improve patient outcomes. This approach requires the development and use of advanced immunochemistry assays to identify specific biomarkers and guide personalized treatment plans. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization promoting individualized treatment approaches, reported that 20 out of 53 new therapeutic molecular entities approved by the Food and Drug Administration in 2023, along with six new gene and cell-based therapies, were classified as personalized medicines. This accounts for approximately 38% of all new molecular entities approved in the U.S. As a result, the rising demand for personalized medicine is driving the growth of the immunochemistry diagnostic devices and equipment market.

Major companies operating in the immunochemistry market are striving to maintain a competitive edge by developing innovative products, including multiplex assays. Multiplex assays are laboratory techniques that enable the simultaneous measurement and analysis of multiple analytes within a single biological sample, offering a comprehensive and efficient means of studying multiple factors or biomarkers in a single experiment. For example, in June 2023, Navigate BioPharma Services, Inc., a biotechnology company based in the United States, introduced new multiplex digital PCR assays designed for precise quantification of chimeric antigen receptor (CAR) T cells, a revolutionary cancer immunotherapy. These assays, based on the Qiagen QIAcuity digital PCR System, allow for the simultaneous measurement of CAR-T cell number, function, and persistence in clinical blood and bone marrow samples, without the need for standard curves. They can detect CAR-T cells at levels as low as 0.01%, providing clinicians with a sensitive, specific, and efficient tool for monitoring responses and safety during clinical trials, thereby facilitating the advancement of CAR-T therapies.

In January 2025, bioMérieux, a France-based in vitro diagnostics company, acquired SpinChip Diagnostics ASA for approximately $159.87 million. This acquisition aims to strengthen bioMérieux’s point-of-care diagnostics capabilities by incorporating SpinChip’s rapid, high-sensitivity immunoassay platform, which can provide results from a whole blood sample in just 10 minutes. SpinChip Diagnostics ASA, a Norway-based company, has a strong reputation for developing point-of-care immunoassays, particularly for cardiac biomarkers.

Major companies operating in the immunochemistry diagnostic devices and equipment market are Abbott Diagnostics, Roche Diagnostics, Siemens Healthcare Diagnostics, Diamond Diagnostics Inc., Dynex Technologies Inc., Grifols S.A., Hycor Biomedical LLC, Immunodiagnostic Systems, Inova Diagnostics, LabCorp, Mindray Medical International Limited, Ortho Clinical Diagnostics, Quest Diagnostics, Randox Laboratories, Sysmex Corporation, ThermoFisher Scientific Inc., Tosoh Bioscience, Danaher Corporation, Johnson & Johnson, Boditech Med Inc., Beckman Coulter Inc., Bio-Rad Laboratories, bioMérieux Clinical Diagnostics, Carolina Liquid Chemistries Corporate, DiaSorin Inc., Agilent Technologies Inc., Merck KGAA, Eagle Biosciences Inc., Biocare Medical LLC, Elabscience Biotechnology Inc., Bio-Genex Laboratories Inc., Diagnostic Biosystem, Histo-Line Laboratories, Rockland Immunochemicals Inc., Abcam plc, Becton Dickinson & Company, Cell Signaling Technology Inc., ImmunoChemistry Technologies LLC, Genemed Biotechnologies Inc., Miltenyi Biotec GmbH, PerkinElmer Inc., Takara Bio. Inc, Immucor Inc., Quidel Corporation.

North America was the largest region in the global immunochemistry diagnostic devices and equipment market in 2025. Asia-Pacific was the second-largest region in the immunochemistry diagnostic devices and equipment market. The regions covered in the immunochemistry diagnostic devices and equipment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunochemistry diagnostic devices and equipment market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

Tariffs are impacting the immunochemistry diagnostic devices and equipment market by increasing costs of imported analyzers, optical components, electronic control units, and specialty reagents used across laboratories and hospitals. North America and Europe are most affected due to reliance on globally sourced diagnostic instruments, while Asia-Pacific faces pricing pressure on consumables and equipment exports. These tariffs are raising procurement costs and slowing laboratory modernization initiatives. However, they are also encouraging regional manufacturing, local reagent production, and greater investment in domestic diagnostic equipment supply chains.

The immunochemistry diagnostic devices and equipment market research report is one of a series of new reports that provides immunochemistry diagnostic devices and equipment market statistics, including immunochemistry diagnostic devices and equipment industry global market size, regional shares, competitors with a immunochemistry diagnostic devices and equipment market share, detailed immunochemistry diagnostic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the immunochemistry diagnostic devices and equipment industry. This immunochemistry diagnostic devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immunochemistry diagnostic devices and equipment are medical tools designed to detect and quantify specific proteins, hormones, or other biomarkers in the body using immune-based reactions. These devices support disease diagnosis, treatment monitoring, and health condition assessment through tests such as hormone assays, cancer marker detection, and infectious disease diagnostics. Essential in laboratories and healthcare facilities, immunochemistry equipment ensures precise and efficient diagnostic testing.

Key product categories in immunochemistry encompass immunochemistry analyzers, immunochemistry stainers, incubators, microscopes, centrifuges, autoclaves, and various consumables. Centrifuges are machines that utilize centrifugal force to separate substances of differing densities, facilitating the removal of moisture or creating gravitational effects. Immunochemistry analyzers come in various types, including chemiluminescence immunoassay (CLIA) analyzers, immunofluorescence (IFA) analyzers, enzyme immunoassay (EIA) analyzers, radioimmunoassay (RIA) analyzers, enzyme-linked fluorescent assay (ELFA) systems, and multiplexed assay systems. Immunochemistry stainers are available in both automated and semi-automated configurations. Consumables for immunochemistry encompass antibodies, antigens, enzymes, reagents, stains, buffers, disposables, and other related items. These immunochemistry tools find applications across diverse fields such as endocrinology, oncology, cardiology, therapeutic drug development and monitoring, infectious disease testing, drug abuse testing, and more. They are utilized by a variety of end-users, including hospitals and clinics, diagnostic laboratories, research labs and institutes, biopharmaceutical and biotechnology companies, among others.

The immunochemistry diagnostic devices and equipment market consists of sales of chemiluminescence immunoassay (CLIA) analyzers, immunofluorescence (IFA) analyzers, enzyme immunoassay (EIA) analyzers, radioimmunoassay (RIA) analyzers, enzyme-linked fluorescent assay (ELFA) systems, and multiplexed assay systems that are used in immunochemistry diagnostics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.